Patents Examined by Gary E. Hollinden
  • Patent number: 9410950
    Abstract: Provided is luminescent gold nanomaterial functionalized by N-(4-aminobutyl)-N-ethylisoluminol, methods of preparation and application thereof. The functionalized gold nanomaterial is formed by N-(4-aminobutyl)-N-ethylisoluminol bonding to the surface of the gold nanoparticle. The functionalized gold nanomaterial are prepared by directly reducing chloroauric acid with N-(4-aminobutyl)-N-ethylisoluminol, wherein N-(4-aminobutyl)-N-ethylisoluminol acts as reducer and stabilizer simultaneously. The preparation method is simple, fast and no need of special conditions. The preparation methods can be performed in a wide temperature range, for example, 15-35.degree. C. The size and pattern of the functionalized gold nanomaterial can be specified by choosing the ratio of chloroauric acid to N-(4-aminobutyl)-N-ethylisoluminol. The obtained functionalized gold nanomaterial exhibits excellent chemiluminescence properties.
    Type: Grant
    Filed: July 8, 2010
    Date of Patent: August 9, 2016
    Assignee: University of Science and Technology of CHINA
    Inventors: Hua Cui, Dayong Tian
  • Patent number: 9380970
    Abstract: The biological test kit is a device for drawing and, optionally, testing biological samples. The biological test kit is an array of lancets set in wells in a rigid base. Each lancet well is covered by a protective cover which when deformed permits the lancet to puncture a user or other patient. In one embodiment the biological test kit employs distinct covers for each lancet and in another the covers are formed from sheet material formed into blisters which cover the lancet.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: July 5, 2016
    Assignee: POPS! Diabetes Care, Inc.
    Inventors: Curtis Jerome Christensen, Daniel William Davis, Erik Daniel Davis
  • Patent number: 9347946
    Abstract: The present invention provides reagents containing binding moieties conjugated to dextran moieties, methods of making such reagents, and use of such reagents in a variety of molecular and cellular assays.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: May 24, 2016
    Assignee: BIOCEPT, INC.
    Inventors: Stephen D. Mikolajczyk, Lisa S. Millar
  • Patent number: 9341575
    Abstract: The application provides methods for the detection of an analyte in a sample by electrochemiluminescence using certain reagent compositions. Reagent compositions, reagent kits for measuring electrochemiluminescence (ECL) and electrochemiluminescence detection methods using the reagent compositions are disclosed. In particular, the application relates to the use of novel combinations of compounds, which can be used in said measurements to provide improved ECL assay performance.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: May 17, 2016
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Andreas Finke, Bernhard Hauptmann, Johannes Stoeckel, Michaela Windfuhr
  • Patent number: 9303286
    Abstract: This invention is in the field of medical devices. Specifically, the present invention provides portable medical devices that allow detection of analytes from a biological fluid. The methods and devices are particularly useful for providing point-of-care testing for a variety of medical applications.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: April 5, 2016
    Assignee: Theranos, Inc.
    Inventors: Ian Gibbons, Shaunak Roy, Edmond Ku
  • Patent number: 9182411
    Abstract: The present invention is directed to methods and devices for detection of cerebrospinal fluid leaks by detection of the CSF protein beta-2 transferrin. The microfluidic devices and methods of the invention combine capture and specific labeling of transferrin from a sample with a subsequent step of isoelectric focusing to separate transferrin isoforms for detection. Microfluidic channels and chambers are patterned on a substrate, designed so that on one region (i.e., a microfluidic channel or chamber) of the substrate transferrin is selectively captured from the sample and labeled, and in a second region of the substrate, transferrin isoforms are separated using isoelectric focusing. Detection of two transferrin bands, indicating the presence of beta-2-transferrin, indicates the presence of CSF in the sample. The devices and methods of the invention provide a safe, efficient, and ultrarapid modality with high specificity and sensitivity for the detection of CSF in the acute care setting.
    Type: Grant
    Filed: June 28, 2010
    Date of Patent: November 10, 2015
    Assignee: COLEN INNOVATIONS, L.L.C.
    Inventor: Chaim BenJoseph Colen
  • Patent number: 9164108
    Abstract: This invention provides novel liposome-based articles of manufacture and microarrays and methods of making and using them (1) to detect the presence of one or more agents in a sample, (2) to determine the amount of one or more agents in a sample, and (3) to determine whether a subject is afflicted with a disorder. This invention also provides kits which comprise the instant microarrays.
    Type: Grant
    Filed: March 22, 2006
    Date of Patent: October 20, 2015
    Assignee: SRI INTERNATIONAL
    Inventors: Denong Wang, Leonore A. Herzenberg, Lawrenes Steinman
  • Patent number: 9110058
    Abstract: A porous solid phase for binding assay that enables a test sample such as whole blood to be analyzed promptly, conveniently, accurately, and inexpensively without requiring a pretreatment, and a binding assay method using said porous solid phase are disclosed. At least one surfactant is incorporated into the porous solid phase for binding assay prior to addition of a test sample, the at least one surfactant being selected from the group consisting of (A) a sugar-containing surfactant that comprises a compound shown by a general formula (I), (B) a sugar-containing surfactant that comprises a sucrose fatty acid ester wherein the constituent fatty acid has 5 to 14 carbon atoms, and (C) a steroid surfactant.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: August 18, 2015
    Assignee: SEKISUI MEDICAL CO., LTD.
    Inventors: Miwako Yoshimizu, Mayumi Kondo, Masashi Tanno
  • Patent number: 9101927
    Abstract: Disclosed is a lateral flow capillary device and uses thereof comprising a unipath bibulous capillary flow matrix and at least two reservoirs each in fluid communication with the capillary flow matrix wherein a reservoir contacts the capillary flow matrix through a passage having a rim pressing the matrix. The pressure that the rim applies on the matrix prevents leakage of liquids out of the capillary flow matrix at the reservoir/matrix interface, allowing accurate sequential draining of liquid from the reservoirs.
    Type: Grant
    Filed: January 31, 2006
    Date of Patent: August 11, 2015
    Assignee: RealBio Technologies Ltd.
    Inventors: Sara Alajem, Avraham Reinhartz
  • Patent number: 9068981
    Abstract: A lateral flow device may include one or more enhancement elements, where the enhancement elements bind to the analyte sandwich to increase a detection signal in the test zone. In preferred embodiments, some or all of the enhancement elements are encapsulated.
    Type: Grant
    Filed: September 19, 2012
    Date of Patent: June 30, 2015
    Assignee: Rapid Pathogen Screening, Inc.
    Inventors: Uma Mahesh Babu, Robert W. VanDine, Robert P. Sambursky
  • Patent number: 9063136
    Abstract: The present invention provides a microfluidic devices and methods of use thereof for the concentration and capture of cells. A pulsed non-Faradaic electric field is applied relative to a sample under laminar flow, which results to the concentration and capture of charged analyte. Advantageously, pulse timing is selected to avoid problems associated with ionic screening within the channel. At least one of the electrodes within the channel is coated with an insulating layer to prevent a Faradaic current from flowing in the channel. Under pulsed application of a unipolar voltage to the electrodes, charged analyte within the sample is moved towards one of the electrodes via a transient electrophoretic force.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: June 23, 2015
    Assignee: QVELLA CORPORATION
    Inventors: Samad Talebpour, Aye Aye Khine, Stephen W. Leonard, Robert Maaskant, Tino Alavie
  • Patent number: 9046526
    Abstract: The present invention refers to a method of determining protein-nucleic acid interaction. The method comprises mixing a protein with a sample comprising a nucleic acid which is suspected to interact with the protein to form a first mixture. The first mixture can be incubated to allow interaction between the protein and nucleic acid. Metallic nanoparticles are added to the first mixture to obtain a second mixture. An electrolyte is added to the first or second mixture to determine the protein-nucleic acid interaction. The present invention also refers to a kit for determining protein-nucleic acid interaction. The kit comprises a protein capable of interacting with a nucleic acid or a nucleic acid capable of interacting with a protein, and at least one type of metallic nanoparticle.
    Type: Grant
    Filed: May 27, 2010
    Date of Patent: June 2, 2015
    Assignee: Agency for Science, Technology and Research
    Inventors: Yen Nee Tan, Xiaodi Su
  • Patent number: 9044441
    Abstract: The invention regards the use of triiodothyronine sulfate, commonly named T3S, as a medicament having thyromimetic activity for the treatment of pathologies due to organic deficiency of triiodothyronine (T3), as such or in association with thyroxine (T4), and pharmaceutical formulations for oral administration thereof.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: June 2, 2015
    Assignee: Bracco S.P.A.
    Inventor: Federico Maisano
  • Patent number: 9034261
    Abstract: A system and method are disclosed in which particles sorted by a flow cytometer may be deposited directly into a deposition layer formed on the surface of an optical disc, and information regarding measurements made of the particle, as well as the storage location of the particle, can be written to the recording layer of the optical disc.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: May 19, 2015
    Assignees: Sony Corporation, Sony Corporation of America
    Inventors: Masanobu Yamamoto, Michael D. Zordan, Gary P. Durack, Larry W. Arnold
  • Patent number: 8993344
    Abstract: Provided is a prozone phenomenon detecting method, by which generation of a prozone phenomenon can be detected even when a conventional specimen analysis tool is used, and examinations using an immunochromatography method and the like can be performed efficiently.
    Type: Grant
    Filed: July 16, 2010
    Date of Patent: March 31, 2015
    Assignee: Arkray, Inc.
    Inventors: Hironori Hasegawa, Kyouichi Ohshiro, Satoshi Fukunaga
  • Patent number: 8993346
    Abstract: Provided herein is a new hybrid material system, mCNT, including magnetic carbon nanotubes for biological and medical sensing applications. In certain embodiments, the systems include magnetic material on the interior of carbon nanotubes (CNTs). The amount of magnetic particles inside CNTs may be such that mCNT can respond to small, low cost, portable magnet. The exterior CNT surface is kept intact for biomolecular attachments or other functionalizations. Performance enhancement with this novel material includes improved sensitivity, reduced response time, and reduced sample volume. According to various embodiments, the mCNTs are substrates for the adherence of molecules participating in these assays or as active sensing elements. Also provided are methods of fabricating two-dimensional mCNT and CNT networks on printed electrodes.
    Type: Grant
    Filed: August 6, 2010
    Date of Patent: March 31, 2015
    Assignee: Nanomix, Inc.
    Inventors: Ray Radtkey, Kanchan Joshi, Bradley N. Johnson, Ying-Lan Chang
  • Patent number: 8951806
    Abstract: The invention concerns a test element for carrying out an immunological sandwich test for determining an analyte from a liquid sample containing a reagent zone or conjugate zone which contains a conjugate of an analyte binding partner and a label which can be detected directly or indirectly by visual, optical or electrochemical means (e.g., an enzyme, fluorescent or direct label, etc.) wherein the conjugate can be dissolved by the liquid sample, a detection zone which contains a permanently immobilized (i.e., which cannot be detached by the liquid sample) binding partner for the analyte or for complexes containing the analyte; and a control zone which contains a permanently immobilized binding partner for the conjugate of analyte binding partner and label characterized in that the control zone additionally contains one or more permanently immobilized binding partner(s) for the analyte or for complexes containing the analyte.
    Type: Grant
    Filed: September 14, 2010
    Date of Patent: February 10, 2015
    Assignee: Roche Diagnostics Operations, Inc.
    Inventor: Juergen Klepp
  • Patent number: 8932877
    Abstract: Disclosed are photoluminescent particles. The particles include a core nano-sized particle of carbon and a passivation agent bound to the surface of the nanoparticle. The passivation agent can be, for instance, a polymeric material. The passivation agent can also be derivatized for particular applications. For example, the photoluminescent carbon nanoparticles can be derivatized to recognize and bind to a target material, for instance a biologically active material, a pollutant, or a surface receptor on a tissue or cell surface, such as in a tagging or staining protocol.
    Type: Grant
    Filed: September 28, 2010
    Date of Patent: January 13, 2015
    Assignee: Clemson University Research Foundation
    Inventor: Ya-Ping Sun
  • Patent number: 8932878
    Abstract: A diagnostic test kit that employs a lateral flow assay device and a plurality of assay reagents for detecting a test analyte within a test sample is disclosed. The assay reagents include detection probes that are capable of producing a detection signal representing the presence or quantity of the test analyte in the test sample. To further enhance detection accuracy, calibration probes are also used that are capable of producing a calibration signal representing the presence or quantity of a calibration analyte. The calibration signal may be utilized to calibrate the detection signal.
    Type: Grant
    Filed: March 31, 2011
    Date of Patent: January 13, 2015
    Assignee: Kimberly-Clark Worldwide, Inc.
    Inventors: Xuedong Song, Chibuese Obi Chidebelu-Eze, Rosann Marie Mathews Kaylor
  • Patent number: 8921121
    Abstract: A chemiluminescence-based detection system and method for counting blood cells by capturing and isolating target blood cells flowing through a microfluidic chip and detecting light emitted by the captured target blood cells.
    Type: Grant
    Filed: August 20, 2010
    Date of Patent: December 30, 2014
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Zuankai Wang, Sau Yin Chin, Samuel K. Sia